2021
In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis
Swanberg KM, Prinsen H, DeStefano K, Bailey M, Kurada AV, Pitt D, Fulbright RK, Juchem C. In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis. NMR In Biomedicine 2021, 34: e4590. PMID: 34318959, DOI: 10.1002/nbm.4590.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisRelapsing-remitting multiple sclerosisMultiple sclerosis patientsMultiple sclerosisDisease durationSclerosis patientsRelapsing-remitting multiple sclerosis patientsSignificant negative correlationAvailable disease-modifying therapiesFrontal cortex metabolismH-MRS protocolDisease-modifying therapiesHealthy control adultsN-acetyl aspartateCross-sectional analysisCortex metabolismMetabolic abnormalitiesΓ-aminobutyric acidMetabolites glutamateFrontal cortexSclerosisNegative correlationControl adultsGABAProton MRS
2012
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal Of Central Nervous System Disease 2012, 4: jcnsd.s6692. PMID: 23650470, PMCID: PMC3619700, DOI: 10.4137/jcnsd.s6692.Peer-Reviewed Original ResearchMultiple sclerosisRelapsing-remitting multiple sclerosisKey clinical trialsDisease-Modifying TherapiesMonoclonal antibody therapyIFN β-1aIFN-β-1bMS includingAvailable efficacyOral agentsGlatiramer acetateTreatment algorithmAntibody therapyClinical trialsPromising therapySafety dataNew therapiesTherapyNew FDATherapeutic landscapeActive investigationNatalizumabFingolimodSclerosisFDA
2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis. Therapeutic Advances In Neurological Disorders 2011, 4: 319-332. PMID: 22010043, PMCID: PMC3187678, DOI: 10.1177/1756285611422108.Peer-Reviewed Original Research